HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program
May 20 2021 - 2:00AM
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today
announces that new analyses and updates on the ongoing studies of
savolitinib, surufatinib, fruquintinib and HMPL-306 will be
presented at the upcoming ASCO21 Virtual Scientific Program, taking
place on June 4-8, 2021.
Aspects of these clinical data disclosures,
alongside its PD-1/L1 combination study strategy and corporate
update will be discussed part of the previously announced call. For
more details, please visit: https://www.hutch-med.com/event/.
SAVOLITINIB
Title: |
Clinical activity of durvalumab and savolitinib in
MET-driven, metastatic papillary renal cancer |
Lead
Author: |
Cristina Suárez, MD, Hospital Univ. Vall D Hebron General |
Session: |
Poster Discussion Session: Genitourinary Cancer—Kidney and
Bladder |
Abstract
Number: |
4511 |
SURUFATINIB
Title: |
Interim analysis results of surufatinib in U.S. patients
with neuroendocrine tumors (NETs). |
Lead Author |
Scott Paulson, MD, Baylor Sammons Cancer Center |
Session: |
Poster Session: Gastrointestinal Cancer—Gastroesophageal,
Pancreatic, and Hepatobiliary |
Abstract
Number: |
4114 |
|
|
Title: |
Surufatinib in combination with toripalimab in patients
with advanced neuroendocrine carcinoma: results from a multicenter,
open-label, single-arm, phase II trial |
Lead Author |
Lin Shen, MD, Peking University Cancer Hospital &
Institute |
Session: |
Online publication only |
Number: |
e16199 |
|
|
Title: |
Phase II trial of surufatinib plus toripalimab for disease
progression after first-line chemotherapy with platinum and
fluoropyrimidine in advanced gastric or gastroesophageal junction
adenocarcinoma |
Lead Author |
Lin Shen, MD, Peking University Cancer Hospital &
Institute |
Session: |
Online publication only |
Number: |
e16040 |
|
|
Title: |
A single-arm, multi-center, open-label phase 2 trial of
surufatinib in patients with unresectable or metastatic biliary
tract cancer. |
Lead Author |
Yuxian Bai, MD, PhD, Harbin Medical University Cancer Hospital |
Session: |
Online publication only |
Number: |
e16123 |
|
|
Title: |
Subgroup analysis by Ki-67 and baseline CgA of the
randomized, placebo-controlled phase 3 study of surufatinib in
advanced well-differentiated pancreatic neuroendocrine tumors
(SANET-p) |
Lead Author |
Xianjun Yu, MD, Fudan University Shanghai Cancer Center |
Session: |
Poster Session: Gastrointestinal Cancer—Gastroesophageal,
Pancreatic, and Hepatobiliary |
Abstract
Number: |
4111 |
|
|
Title: |
An open-label phase 1b/2 study of surufatinib in
combination with tislelizumab in subjects with advanced solid
tumors |
Lead Author |
Arvind Dasari, MD, MS, MD Anderson Cancer Center |
Session: |
Poster Session: Developmental Therapeutics—Immunotherapy |
Abstract
Number: |
TPS2677 |
FRUQUINTINIB
Title: |
Preliminary results of a phase 1b study of fruquintinib
plus sintilimab in advanced colorectal cancer |
Lead Author |
Ye Guo, MD, Shanghai East Hospital |
Session: |
Poster Discussion Session: Gastrointestinal Cancer—Colorectal and
Anal |
Abstract
Number: |
2514 |
|
|
Title: |
A phase Ib trial of assessing the safety and preliminary
efficacy of a combination therapy of Geptanolimab (GB 226) plus
Fruquintinib in patients with metastatic colorectal cancer
(mCRC) |
Lead Author |
Yanzhi Cui, MD, Tumour Institute, Fourth Hospital of Hebei Medical
University |
Session: |
Online publication only |
Number: |
e15551 |
HMPL-306
Title: |
A multicenter open-label phase 1 study evaluating the
safety and tolerability of HMPL-306 in patients with locally
advanced or metastatic solid tumors with IDH
mutations. |
Lead Author |
Filip Janku, MD, MD Anderson Cancer Center |
Session: |
Poster Session: Developmental Therapeutics—Molecularly Targeted
Agents and Tumor Biology |
Abstract
Number: |
TPS3159 |
About Savolitinib
Savolitinib is an oral, potent, and highly
selective small molecule inhibitor of MET, a receptor tyrosine
kinase which has been shown to function abnormally in many types of
solid tumors promoting tumor growth, angiogenesis, and metastasis.
Savolitinib has been studied in over 1,100 patients to date. In
clinical studies, it has shown promising clinical efficacy in
patients with MET gene alterations in multiple tumor types with an
acceptable safety profile.
In 2011, HUTCHMED entered into a global
licensing and joint development and commercialization agreement
with AstraZeneca PLC (LSE/STO/NYSE: AZN) for savolitinib.
Savolitinib’s global development plan includes non-small cell lung
cancer (NSCLC) and kidney cancer, and additional MET-driven tumors
are being explored.
About Surufatinib
Surufatinib is a novel, oral angio-immuno kinase
inhibitor that selectively inhibits the tyrosine kinase activity
associated with vascular endothelial growth factor receptor
(“VEGFR”) and fibroblast growth factor receptor (FGFR), which both
inhibit angiogenesis, and colony stimulating factor-1 receptor
(CSF-1R), which regulates tumor-associated macrophages, promoting
the body’s immune response against tumor cells. Its unique dual
mechanism of action may be very suitable for possible combinations
with other immunotherapies, where there may be synergistic
anti-tumor effects.
HUTCHMED currently retains all rights to
surufatinib worldwide.
About Fruquintinib
Fruquintinib is a highly selective and potent
oral inhibitor of VEGFRs -1, -2 and -3. VEGFR inhibitors play a
pivotal role in blocking tumor angiogenesis. Fruquintinib was
designed to improve kinase selectivity to minimize off-target
toxicities, improve tolerability and provide more consistent target
coverage. The generally good tolerability in patients to date,
along with fruquintinib’s low potential for drug-drug interaction
based on preclinical assessment, suggests that it may also be
highly suitable for combinations with other anti-cancer
therapies.
HUTCHMED retains all rights to fruquintinib
outside of China. In China, HUTCHMED is partnered with Eli Lilly
and Company and is responsible for development and execution of all
on-the-ground medical detailing, promotion and local and regional
marketing.
About HMPL-306
HMPL-306 is HUTCHMED’s ninth innovative oncology
drug candidate that it has discovered that has entered clinical
development and the sixth to enter global clinical development.
Cytoplasmic mutant IDH1 and mitochondrial mutant IDH2 have been
known to switch to the other form when targeted by an inhibitor of
IDH1 mutant alone or IDH2 mutant alone. By targeting both IDH1 and
IDH2 mutations, HMPL-306 could potentially provide therapeutic
benefits in cancer patients harboring either IDH mutation, and may
address acquired resistance to IDH inhibition through isoform
switching.
HUTCHMED currently retains all rights to
HMPL-306 worldwide.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM) (formerly Hutchison
China MediTech) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and
global development and commercialization of targeted therapies and
immunotherapies for the treatment of cancer and immunological
diseases. A dedicated organization of over 1,200 personnel has
advanced ten cancer drug candidates from in-house discovery into
clinical studies around the world, with its first two oncology
drugs now approved and launched. For more information, please
visit: www.hutch-med.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the “safe harbor” provisions of
the U.S. Private Securities Litigation Reform Act of 1995. These
forward-looking statements can be identified by words like “will,”
“expects,” “anticipates,” “future,” “intends,” “plans,” “believes,”
“estimates,” “pipeline,” “could,” “potential,” “first-in-class,”
“designed to,” “objective,” “guidance,” “pursue,” or similar terms,
or by express or implied discussions regarding potential drug
candidates, potential indications for drug candidates or by
discussions of strategy, plans, expectations or intentions. You
should not place undue reliance on these statements. Such
forward-looking statements are based on the current beliefs and
expectations of management regarding future events, and are subject
to significant known and unknown risks and uncertainties. Should
one or more of these risks or uncertainties materialize, or should
underlying assumptions prove incorrect, actual results may vary
materially from those set forth in the forward-looking statements.
There can be no guarantee that any of our drug candidates will be
approved for sale in any market, or that any approvals which are
obtained will be obtained at any particular time, or that any such
drug candidates will achieve any particular revenue or net income
levels. In particular, management’s expectations could be affected
by, among other things: unexpected regulatory actions or delays or
government regulation generally; the uncertainties inherent in
research and development, including the inability to meet our key
study assumptions regarding enrollment rates, timing and
availability of subjects meeting a study’s inclusion and exclusion
criteria and funding requirements, changes to clinical protocols,
unexpected adverse events or safety, quality or manufacturing
issues; the inability of a drug candidate to meet the primary or
secondary endpoint of a study; the inability of a drug candidate to
obtain regulatory approval in different jurisdictions or gain
commercial acceptance after obtaining regulatory approval; global
trends toward health care cost containment, including ongoing
pricing pressures; uncertainties regarding actual or potential
legal proceedings, including, among others, actual or potential
product liability litigation, litigation and investigations
regarding sales and marketing practices, intellectual property
disputes, and government investigations generally; the impact of
the COVID-19 pandemic or other health crises in China or globally
on general economic, regulatory and political conditions; and
general economic and industry conditions, including uncertainties
regarding the effects of the persistently weak economic and
financial environment in many countries and uncertainties regarding
future global exchange rates. For further discussion of these and
other risks, see HUTCHMED’s filings with the U.S. Securities and
Exchange Commission and on AIM. HUTCHMED is providing the
information in this press release as of this date and does not
undertake any obligation to update any forward-looking statements
as a result of new information, future events or
otherwise.
CONTACTS
Investor Enquiries |
|
Mark Lee, Senior Vice President |
+852 2121 8200 |
Annie Cheng, Vice President |
+1 (973) 567 3786 |
|
|
Media Enquiries |
|
Americas – Brad Miles, Solebury Trout |
+1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com |
Europe – Ben Atwell / Alex Shaw, FTI
Consulting |
+44 20 3727 1030 /
+44 7771 913 902 (Mobile) /
+44 7779 545 055 (Mobile)
HUTCHMED@fticonsulting.com |
Asia – Joseph Chi Lo / Zhou Yi, Brunswick |
+852 9850 5033 (Mobile)
/ +852 9783 6894 (Mobile)
HUTCHMED@brunswickgroup.com |
|
|
Nominated Advisor |
|
Freddy Crossley / Atholl Tweedie, Panmure Gordon
(UK) Limited |
+44 (20) 7886 2500 |
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024